L-Arginine and Improved Pain-Free Walking Distance

Doses used in studies

g/day: 6 (median 6, IQR 6–6) — 1 study

Time to effect

Median: 4.3 weeks · IQR 4.3 weeks–4.3 weeks · Range 4.3 weeks–4.3 weeks — Reported in 1 of 1 study

Safety in these studies

Overall tolerabilityReported
No significant effects were observed on ABI (right or left) or on cholesterol and triglyceride concentrations.
from: Assessment of the effectiveness and safety of two-month oral supplementation with L-argini

1 of 1 paper

Assessment of the effectiveness and safety of two-month oral supplementation with L-arginine depending on the type of lipid metabolism disorder in patients with atherosclerotic lower limb ischemia.

2025-10-01
RCT · n = 100
Journal of physiology and pharmacology : an official journal of the Polish Physiological Society 76(5)
- M Micker
- N Balcer-Dymel
- M Czerwonka
- B Madej
- E Swiecka
- P A Kolodziejski
- E Pruszynska-Oszmalek
- Z Checinska-Maciejewska
- H Krauss
- A Rekas-Dudziak

PubMed: 41364169
DOI: 10.26402/jpp.2025.5.05

8 Insights on

Improved Pain-Free Walking Distance

High evidence
Large Human Trial
Clinical

After 30 and 60 days, significant increases in ... extended PFWD (p<0.001) were observed across all subgroups receiving L-arginine compared with controls.

Effect: Beneficial
Effect size: Moderate
Significant: Yes
Dose: 6 g/day